PCI vs. CABG
ProcedurePCI vs. CABG
NCT Number: NCT04968977
Left main (LM) coronary artery disease is associated with high morbidity and mortality owing to the large myocardial territory at risk for ischemia. Evidence from randomized controlled trials supports that percutaneous coronary intervention (PCI) with drug-eluting stents (DES) for LM disease is an acceptable treatment strategy compared with coronary artery bypass graft surgery in patients with low or intermediate anatomic complexity. However in-stent restenosis (ISR) after DES in LM disease is still occurring with an incidence of 9,7%. Studies comparing the percutaneous coronary intervention with coronary artery bypass grafting (CABG) in the treatment of in-stent restenosis in unprotected left main have been scarce. While surgical revascularization is considered to be the standard treatment for this kind of stent failure, owing to a high risk of perioperative morbidity and mortality, the restoration of flow with PCI may be a reliable alternative. Additionally, it is not clear whether re-PCI is safe in these patients. Therefore, the purpose of the present study was to compare long-term outcomes following PCI or CABG for UPLM-ISR disease.
Looking for future studies?
Notify MeObservational
Fabrizio D'Ascenzo, Turin, Italy
Only the study team can determine whether someone qualifies for participation.
Patients were divided into two separate cohorts for the analyses. The data included consecutive patients with ≥50% diameter UPLM-ISR, with or without multivessel coronary artery disease. Patients with an equivalent of UPLM-ISR: left main distal bifurcation disease, within the proximal 5 mm of the left anterior descending artery (LAD) or left circumflex artery (LCx) ostium (in the absence of significant angiographic stenosis in the left main coronary artery), were eligible. Patients who had protected LM-ISR, defined as the occurrence of at least one patent arterial or venous graft to the left coronary artery, other concomitant non-CABG procedure during surgery, were excluded.
PCI vs. CABG
Time frame: 4 years
Time frame: 4 years
Time frame: 4 years
Time frame: 4 years
Time frame: 4 years
Medical University of Silesia
Other
Long-term Outcomes Following Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting for Treating In-stent Restenosis in Unprotected Left Main Coronary Artery: Multicenter LM-DRAGON Registry
Acronym: LM-DRAGON
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03767621
Arterial Occlusive Diseases, Arteriosclerosis
Terrassa, Barcelona, Spain
View Trial DetailsNCT06972225
Bifurcation Coronary Disease, Cardiovascular Diseases
Québec, Quebec, Canada
View Trial DetailsNCT01205789
Arterial Occlusive Diseases, Arteriosclerosis
Santa Clara, California, United States
View Trial DetailsNCT04475380
Acute Coronary Syndrome, Angina Pectoris
Enschede, Netherlands
View Trial Details